Cadrenal Therapeutics Wins FDA Alignment for Phase 3 HIT Study

Cadrenal Therapeutics announced FDA alignment on the primary endpoint and trial design for CAD-1005, a first-in-class therapy for heparin-induced thrombocytopenia. The agreement positions the company to advance its phase 3 registrational study for this high-value condition.